$TPAC We are holding very nicely, forming a base around

New Post Public Reply Private Reply Replies (4) Message Board
Mysterium
$TPAC We are holding very nicely, forming a base around .003, and keeping the RSI cool, priming it for a run. This is indicative of an inability to manipulate the stock in either direction in the immediate sense. We are on the cusp of some very significant announcements, likely to precipitate further news both in regards to them and in addition to them.

Bill is currently in China meeting with investment bankers and finalizing terms that will undoubtedly lead to the closing of acquisitions and likely, a joint venture as well. As we hover here and the noise has yet to let up, traders must ask themselves one fundamental question: Which side of the acquisition news do I want to be on? The proximity of the closing of the antecedent deals gives credence to much of the due diligence here in support of an increased(and increasing) operational change within the company, thus leading to triplicate an ascension in manufacturing, diversification of potential product portfolio, and a forward moving change in revenues. With one of the acquisitive targets being currently profitable and the other having been mentioned as needing little less than a quick turnaround to be of a similarly profitable nature, we will soon be sitting on higher ground, with a larger intrinsic value than now, even upon current speculation of such. There has also been mention of a possible third acquisition, which for now, I would consider nothing more than an X-factor until more is revealed.

Our paperwork has now been submitted and is in the hands of Boeing. A little more back-and-forth, and we should hear something in consideration of that as well. Likely, this will be timed in proper accordance with the transpiration of events to unfold in China. To the effect of imagination, my thoughts on this stand to reason that first the Harbin JV will be announced, then the acquisitions, then Boeing. With so much in the works here, there are many other items of significance the can precede, disrupt the timeline of, or follow this order.

Recent news has divulged that our $100k purchase order was worth much more than its monetary value. What does that mean, potentially? When scrolling through the timeline on the company's preferred online communication source, there has been mention of COMAC, a Chinese aircraft manufacturer, multiple times. It was mentioned that we trialed sixty-eight parts for COMAC. In a later communication, an inquisitor gave follow to this, asking if there were any more trial parts being made. In reply, the company noted that no more trial parts were needed, for approval was already granted. Due to the sensitive nature of relationships with larger players, it may have been deemed most strategically prosperous to delay disclosure of the purchaser and the relationship therein. Another factor of probability lends further prospect to the likelihood of doing business with COMAC. What is that, one might ask? Simple; it's NAVAIR. COMAC's C919 174 person passenger jet, has now been considered China's rival to similar aircraft by Boeing and Airbus. Upon being cognizant of the fact that we are the only company in China that is NAVAIR certified, the next logical step is to conclude the feasibility of putting the two entities together, us and them. Not only does COMAC get the better part, but they also stand to save significantly in importation, with the inherent honor of getting chance to purchase domestic goods.

On the way as well, we have the launch of our automotive sector as it pertains to bearings, with Jason Wenig, automotive connoisseur and brother of ebay CEO, Devin Wenig, acting as liaison between the worlds of aerospace and automotive, thus providing his contacts with bearings that are NAVAIR certified and rendered superior even in the aviation arena. Maritime is on the mid to near-term horizon as well. And with our recent connection to the Australian marketing firm, we will be supplying Australia, home to Boeing's second largest footprint outside of the US(with 27 locations), SE Asia, and the Middle East with bearings for, but not limited to, aerospace, mining, automotive, maritime. With the way the future is headed, I do not see it to be unreasonable to assume that we will eventually customize, manufacture, and supply parts for various specializations within the growing robotics industry as well. And with the present being what it is in tandem, doing the same for heavy industrial machinery is by no means a stretch either.

We have a very significant turning of events here. Our company is on pace to become a major international player within the confines of not one, but many, pertinent industries. Our share structure is continuously diminishing via the ongoing O/S retirement program. Our investor sentiment is becoming increasingly more resilient to chart-based setbacks or fearful sells out of impatience, and is absorbing remaining shares. Short interest has been highly prevalent, and covering will be needed on an ongoing basis as well, further serving to tie up the float, as many of those with short positions are savvy and are covering to add to long positions, playing both sides profitably. All said, it is only a matter of time before such news is released that we are rendered by one and all as a different company than we were the day before that announcement arrived. We go from speculation to certainty. And upon such certainty, we are thus eyed more and more as a sure thing to buyers on the sidelines. As our price per share climbs, we attract a new type of investor. Each time a zero is removed and the decimal place moves right, more will opt in along side us. And what a favorable time to do so. There will be a shrinking of the share structure, with the supply and demand ratio much in favor of the demand side. There will be little to sell here and every reason to buy. We are sitting on higher ground here and one can only envision how far we are set to climb.

Trans-Pacific Aerospace (TPAC) Stock Research Links

TPAC Board Company Profile Buy Rating Time & Sales News Filings Financials
Do your own DD. Assume everyone here is either an amateur trader/investor or a paid interest such as a compensated pumper/basher. My posts are strictly for entertainment purposes. I am not on Wall St., do not work for a group, and only get paid when my personal investments materialize. I am only responsible for my own gains and losses; no one is to blame for my mistakes or for any advice taken from postings; likewise, I am not to blame for any advice you take of mine, regardless of gains or losses from doing so. Good luck to all; may you live long and prosper greatly.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

Updated Category News Views 107

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Continue Reading
LINE-X Seeks Veterans to Propel Franchise Growth

Updated Category News Views 55

If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 106

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading
Key Insights Await in Sectra's Six-Month Report

Updated Category News Views 75

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 28

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Accro's Vitiligo Trial Moves Fast with Fosun's Boost

Updated Category News Views 112

Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 51

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 73

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 78

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading